Explore
← New search
Filters:
1
✕
in vivo tumor growth/act efficacy study
✕
cd8+ tils (ot1 and endogenous cd44+) from b16-ova tumors in mice
✕
clear all
1 matching publication(s)
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
PMID 37081150 · Nat Immunol · 2023
L1
37/100